---
document_datetime: 2025-12-02 05:53:13
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/cuprior.html
document_name: cuprior.html
version: success
processing_time: 0.1127105
conversion_datetime: 2025-12-29 20:00:48.482709
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Cuprior

[RSS](/en/individual-human-medicine.xml/65930)

##### Authorised

This medicine is authorised for use in the European Union

trientine Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Cuprior](#news-on)
- [More information on Cuprior](#more-information-on-cuprior-565)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Cuprior. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Cuprior.

For practical information about using Cuprior, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Cuprior and what is it used for?

Cuprior is a medicine used to treat patients aged 5 years and older with Wilson's disease, a genetic condition in which copper absorbed from food builds up in the body, particularly in the liver and the brain, causing damage. Cuprior is used in patients who cannot take D-penicillamine, another medicine for this condition.

Cuprior contains the active substance trientine. It is a hybrid medicine. This means that it is similar to a 'reference medicine' (in this case Trientine Dihydrochloride 300 mg capsules) also containing trientine. The difference between Cuprior and the reference medicine is that Cuprior contains another form of trientine (trientine tetrahydrochloride) and does not need to be stored in a refrigerator.

## How is Cuprior used?

Cuprior can only be obtained with a prescription and treatment should be started by a specialist with experience in the management of Wilson's disease.

Cuprior is available as 150 mg tablets. In adults, the total recommended daily dose is from 3 to 6.5 tablets, and in children from 1.5 to 4 tablets. The tablets are taken in 2 to 4 divided doses. Doses are adjusted according to patient response and levels of copper in the body. Cuprior should be taken on an empty stomach, at least one hour before or two hours after meals.

For further information, see the package leaflet.

## How does Cuprior work?

The active substance in Cuprior, trientine, is a chelating agent. It works by attaching to copper in the body and forming a complex that is then eliminated in the urine.

## How has Cuprior been studied?

The company provided data from the published literature, which show that trientine significantly increases copper elimination in the urine.

The company also carried out a study to compare the levels of trientine in the blood after having taken Cuprior with those for the reference medicine. Results showed that Cuprior produces higher levels of the active substance in the blood than the reference medicine. To take account of this difference, Cuprior is used at lower doses.

## What are the benefits and risks of Cuprior?

Since Cuprior is a hybrid medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Cuprior approved?

The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Cuprior's benefits are greater than its risks and recommended that it be approved for use in the EU.

The CHMP noted that trientine has been used for over 30 years to treat patients with Wilson's disease. Although Cuprior releases more trientine in the body than the reference medicine, this difference can be addressed by lowering the dose, which is in any case adjusted according to patient response and levels of copper in the body.

## What measures are being taken to ensure the safe and effective use of Cuprior?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Cuprior have been included in the summary of product characteristics and the package leaflet.

## Other information about Cuprior

The European Commission granted a marketing authorisation valid throughout the European Union for Cuprior on 5 September 2017.

For more information about treatment with Cuprior, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Cuprior : EPAR - Summary for the public

Reference Number: EMA/267439/2017

English (EN) (74.16 KB - PDF)

**First published:** 03/10/2017

**Last updated:** 03/10/2017

[View](/en/documents/overview/cuprior-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-906)

български (BG) (98.8 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

03/10/2017

[View](/bg/documents/overview/cuprior-epar-summary-public_bg.pdf)

español (ES) (72.25 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

03/10/2017

[View](/es/documents/overview/cuprior-epar-summary-public_es.pdf)

čeština (CS) (96.64 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

03/10/2017

[View](/cs/documents/overview/cuprior-epar-summary-public_cs.pdf)

dansk (DA) (71.85 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

03/10/2017

[View](/da/documents/overview/cuprior-epar-summary-public_da.pdf)

Deutsch (DE) (74.14 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

03/10/2017

[View](/de/documents/overview/cuprior-epar-summary-public_de.pdf)

eesti keel (ET) (71.12 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

03/10/2017

[View](/et/documents/overview/cuprior-epar-summary-public_et.pdf)

ελληνικά (EL) (101.25 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

03/10/2017

[View](/el/documents/overview/cuprior-epar-summary-public_el.pdf)

français (FR) (72.77 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

03/10/2017

[View](/fr/documents/overview/cuprior-epar-summary-public_fr.pdf)

hrvatski (HR) (91.09 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

03/10/2017

[View](/hr/documents/overview/cuprior-epar-summary-public_hr.pdf)

italiano (IT) (71.63 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

03/10/2017

[View](/it/documents/overview/cuprior-epar-summary-public_it.pdf)

latviešu valoda (LV) (93.77 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

03/10/2017

[View](/lv/documents/overview/cuprior-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (94.72 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

03/10/2017

[View](/lt/documents/overview/cuprior-epar-summary-public_lt.pdf)

magyar (HU) (90.99 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

03/10/2017

[View](/hu/documents/overview/cuprior-epar-summary-public_hu.pdf)

Malti (MT) (96.19 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

03/10/2017

[View](/mt/documents/overview/cuprior-epar-summary-public_mt.pdf)

Nederlands (NL) (72.08 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

03/10/2017

[View](/nl/documents/overview/cuprior-epar-summary-public_nl.pdf)

polski (PL) (96.74 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

03/10/2017

[View](/pl/documents/overview/cuprior-epar-summary-public_pl.pdf)

português (PT) (72.02 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

03/10/2017

[View](/pt/documents/overview/cuprior-epar-summary-public_pt.pdf)

română (RO) (92.67 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

03/10/2017

[View](/ro/documents/overview/cuprior-epar-summary-public_ro.pdf)

slovenčina (SK) (95.06 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

03/10/2017

[View](/sk/documents/overview/cuprior-epar-summary-public_sk.pdf)

slovenščina (SL) (89.57 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

03/10/2017

[View](/sl/documents/overview/cuprior-epar-summary-public_sl.pdf)

Suomi (FI) (71.52 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

03/10/2017

[View](/fi/documents/overview/cuprior-epar-summary-public_fi.pdf)

svenska (SV) (71.69 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

03/10/2017

[View](/sv/documents/overview/cuprior-epar-summary-public_sv.pdf)

## Product information

Cuprior : EPAR - Product Information

English (EN) (325.83 KB - PDF)

**First published:** 03/10/2017

**Last updated:** 23/07/2025

[View](/en/documents/product-information/cuprior-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-996)

български (BG) (349.48 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

23/07/2025

[View](/bg/documents/product-information/cuprior-epar-product-information_bg.pdf)

español (ES) (304.05 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

23/07/2025

[View](/es/documents/product-information/cuprior-epar-product-information_es.pdf)

čeština (CS) (347.58 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

23/07/2025

[View](/cs/documents/product-information/cuprior-epar-product-information_cs.pdf)

dansk (DA) (297 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

23/07/2025

[View](/da/documents/product-information/cuprior-epar-product-information_da.pdf)

Deutsch (DE) (326.05 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

23/07/2025

[View](/de/documents/product-information/cuprior-epar-product-information_de.pdf)

eesti keel (ET) (306.16 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

23/07/2025

[View](/et/documents/product-information/cuprior-epar-product-information_et.pdf)

ελληνικά (EL) (356.44 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

23/07/2025

[View](/el/documents/product-information/cuprior-epar-product-information_el.pdf)

français (FR) (292.56 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

23/07/2025

[View](/fr/documents/product-information/cuprior-epar-product-information_fr.pdf)

hrvatski (HR) (328.65 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

23/07/2025

[View](/hr/documents/product-information/cuprior-epar-product-information_hr.pdf)

íslenska (IS) (263.4 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

23/07/2025

[View](/is/documents/product-information/cuprior-epar-product-information_is.pdf)

italiano (IT) (290.05 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

23/07/2025

[View](/it/documents/product-information/cuprior-epar-product-information_it.pdf)

latviešu valoda (LV) (337.63 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

23/07/2025

[View](/lv/documents/product-information/cuprior-epar-product-information_lv.pdf)

lietuvių kalba (LT) (332.78 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

23/07/2025

[View](/lt/documents/product-information/cuprior-epar-product-information_lt.pdf)

magyar (HU) (363.67 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

23/07/2025

[View](/hu/documents/product-information/cuprior-epar-product-information_hu.pdf)

Malti (MT) (390.55 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

23/07/2025

[View](/mt/documents/product-information/cuprior-epar-product-information_mt.pdf)

Nederlands (NL) (303.35 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

23/07/2025

[View](/nl/documents/product-information/cuprior-epar-product-information_nl.pdf)

norsk (NO) (272.07 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

23/07/2025

[View](/no/documents/product-information/cuprior-epar-product-information_no.pdf)

polski (PL) (351.75 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

23/07/2025

[View](/pl/documents/product-information/cuprior-epar-product-information_pl.pdf)

português (PT) (318.23 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

23/07/2025

[View](/pt/documents/product-information/cuprior-epar-product-information_pt.pdf)

română (RO) (349.64 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

23/07/2025

[View](/ro/documents/product-information/cuprior-epar-product-information_ro.pdf)

slovenčina (SK) (360.8 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

23/07/2025

[View](/sk/documents/product-information/cuprior-epar-product-information_sk.pdf)

slovenščina (SL) (332.14 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

23/07/2025

[View](/sl/documents/product-information/cuprior-epar-product-information_sl.pdf)

Suomi (FI) (307.84 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

23/07/2025

[View](/fi/documents/product-information/cuprior-epar-product-information_fi.pdf)

svenska (SV) (290.23 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

23/07/2025

[View](/sv/documents/product-information/cuprior-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0029 25/03/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Cuprior : EPAR - All Authorised presentations

English (EN) (7.89 KB - PDF)

**First published:** 03/10/2017

**Last updated:** 16/10/2019

[View](/en/documents/all-authorised-presentations/cuprior-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-449)

български (BG) (50.18 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

16/10/2019

[View](/bg/documents/all-authorised-presentations/cuprior-epar-all-authorised-presentations_bg.pdf)

español (ES) (8.69 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

16/10/2019

[View](/es/documents/all-authorised-presentations/cuprior-epar-all-authorised-presentations_es.pdf)

čeština (CS) (25.6 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

16/10/2019

[View](/cs/documents/all-authorised-presentations/cuprior-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (8.13 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

16/10/2019

[View](/da/documents/all-authorised-presentations/cuprior-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (8.07 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

16/10/2019

[View](/de/documents/all-authorised-presentations/cuprior-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (8.49 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

16/10/2019

[View](/et/documents/all-authorised-presentations/cuprior-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (50.31 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

16/10/2019

[View](/el/documents/all-authorised-presentations/cuprior-epar-all-authorised-presentations_el.pdf)

français (FR) (7.88 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

16/10/2019

[View](/fr/documents/all-authorised-presentations/cuprior-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (24.92 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

16/10/2019

[View](/hr/documents/all-authorised-presentations/cuprior-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (7.99 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

16/10/2019

[View](/is/documents/all-authorised-presentations/cuprior-epar-all-authorised-presentations_is.pdf)

italiano (IT) (8.18 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

16/10/2019

[View](/it/documents/all-authorised-presentations/cuprior-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (45.95 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

16/10/2019

[View](/lv/documents/all-authorised-presentations/cuprior-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (45.91 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

16/10/2019

[View](/lt/documents/all-authorised-presentations/cuprior-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (46.77 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

16/10/2019

[View](/hu/documents/all-authorised-presentations/cuprior-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (45.79 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

16/10/2019

[View](/mt/documents/all-authorised-presentations/cuprior-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (7.86 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

16/10/2019

[View](/nl/documents/all-authorised-presentations/cuprior-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (43.16 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

16/10/2019

[View](/no/documents/all-authorised-presentations/cuprior-epar-all-authorised-presentations_no.pdf)

polski (PL) (25.98 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

16/10/2019

[View](/pl/documents/all-authorised-presentations/cuprior-epar-all-authorised-presentations_pl.pdf)

português (PT) (8.64 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

16/10/2019

[View](/pt/documents/all-authorised-presentations/cuprior-epar-all-authorised-presentations_pt.pdf)

română (RO) (45.32 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

16/10/2019

[View](/ro/documents/all-authorised-presentations/cuprior-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (46.64 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

16/10/2019

[View](/sk/documents/all-authorised-presentations/cuprior-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (45.26 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

16/10/2019

[View](/sl/documents/all-authorised-presentations/cuprior-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (8.2 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

16/10/2019

[View](/fi/documents/all-authorised-presentations/cuprior-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (8.31 KB - PDF)

**First published:**

03/10/2017

**Last updated:**

16/10/2019

[View](/sv/documents/all-authorised-presentations/cuprior-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Cuprior Active substance trientine tetrahydrochloride International non-proprietary name (INN) or common name trientine Therapeutic area (MeSH) Hepatolenticular Degeneration Anatomical therapeutic chemical (ATC) code A16AX

### Pharmacotherapeutic group

Other alimentary tract and metabolism products

### Therapeutic indication

Cuprior is indicated for the treatment of Wilson's disease in adults, adolescents and children ≥ 5 years intolerant to D-penicillamine therapy.

## Authorisation details

EMA product number EMEA/H/C/004005 Marketing authorisation holder

Orphalan

226 Boulevard Voltaire 75011 Paris France

Opinion adopted 21/04/2017 Marketing authorisation issued 05/09/2017 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Cuprior : EPAR - Procedural steps taken and scientific information after the authorisation

English (EN) (134.98 KB - PDF)

**First published:** 06/11/2018

**Last updated:** 26/03/2024

[View](/en/documents/procedural-steps-after/cuprior-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Cuprior-H-C-PSUSA-00010637-201809 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/419515/2019

English (EN) (69.25 KB - PDF)

**First published:** 24/07/2019

[View](/en/documents/scientific-conclusion/cuprior-h-c-psusa-00010637-201809-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Cuprior : EPAR - Public assessment report

Adopted

Reference Number: EMA/308946/2017

English (EN) (793.76 KB - PDF)

**First published:** 03/10/2017

**Last updated:** 03/10/2017

[View](/en/documents/assessment-report/cuprior-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Cuprior

Adopted

Reference Number: EMA/CHMP/665612/2017

English (EN) (75.24 KB - PDF)

**First published:** 21/04/2017

**Last updated:** 21/04/2017

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-cuprior_en.pdf)

#### News on Cuprior

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 April 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-april-2017) 21/04/2017

#### More information on Cuprior

This product is no longer an [orphan medicine](/en/medicines/human/orphan-designations/eu3151471) . It was originally designated an orphan medicine on 19 March 2015. Cuprior was withdrawn from the Community register of orphan medicinal products by the European Commission in July 2017, at the time of the granting of a marketing authorisation.

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 26/03/2024

## Share this page

[Back to top](#main-content)